9 Results for "

Rezetecan

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "Rezetecan" in MCE Product Catalog:

Cat. No.: HY-147408
Purity:  99.60%
Synonyms: SHR9265
Research Areas:  

Cancer

Rezetecan is a topoisomerase I inhibitor with cytotoxicity. Rezetecan can serve as an antibody-drug conjugate payload (ADC Payloads), for example, it participates in the synthesis of Tizetatug rezetecan (HY-177711). Rezetecan is applicable to research related to various cancers such as breast cancer and gastric cancer .
loading...
    loading...
Cat. No.: HY-164762
CAS No.: 2924909-11-3
Synonyms: SHR-A1811
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
loading...
    loading...
Cat. No.: HY-P991703
CAS No.: 3042847-92-4
Synonyms: GSK5733584 antibody; HS-20089 antibody; hu2F7

Target:  

CD276/B7-H3

Research Areas:  

Cancer

Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting B7-H4/VTCN1. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280) .
loading...
    loading...
Cat. No.: HY-177711
CAS No.: 2938864-88-9
Synonyms: SHR-A1921
Research Areas:  

Cancer

Tizetatug rezetecan (SHR-A1921) is an Antibody-drug Conjugate (ADC) composed of antibody Tizetatug (HY-P991032) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Tizetatug rezetecan can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-185761A
Research Areas:  

Others

ADC Control Human IgG1-rezetecan (DAR4) is an isotype control antibody-drug conjugate (ADC) consisting of a human IgG1 antibody conjugated to Rezetecan (HY-147408) with a drug-to-antibody ratio (DAR) of 4 .
loading...
    loading...
Cat. No.: HY-185761
Research Areas:  

Others

ADC Control Human IgG1-rezetecan is an isotype-matched control antibody-drug conjugate (ADC) for Mocertatug rezetecan (HY-185280). Mocertatug rezetecan is an ADC targeting B7-H4 .
loading...
    loading...
Cat. No.: HY-185279
CAS No.: 3042849-33-9
Synonyms: HS-20093; GSK5764227
Research Areas:  

Cancer

Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-185280
CAS No.: 3042848-25-6
Synonyms: HS-20089 (DAR6); GSK5733584 (DAR6)
Research Areas:  

Cancer

Mocertatug rezetecan (DAR6) (HS-20089 (DAR6); GSK5733584 (DAR6)) is an antibody-drug conjugate (ADC) targeting B7-H4, composed of Mocertatug (HY-P991703) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Mocertatug rezetecan (DAR6) delivers a TOPO1 inhibitor payload. It binds to B7-H4-expressing tumor cells, triggers ADC internalization, and induces S-phase cell cycle arrest, cytotoxicity, and bystander killing effect. Mocertatug rezetecan (DAR6) exhibits dose-dependent tumor growth inhibition in breast cancer and endometrial cancer CDX models. It can be used in research related to platinum-resistant ovarian cancer, breast cancer, endometrial cancer, cholangiocarcinoma, and cervical cancer .
loading...
    loading...
Cat. No.: HY-185280A
CAS No.: 3042848-25-6
Synonyms: HS-20089 (DAR4); GSK5733584 (DAR4)
Research Areas:  

Cancer

Mocertatug rezetecan (DAR4) (HS-20089 (DAR4); GSK5733584 (DAR4)) is an antibody-drug conjugate (ADC) targeting B7-H4, composed of Mocertatug (HY-P991703) and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan (HY-148668). Mocertatug rezetecan (DAR4) delivers a TOPO1 inhibitor payload. It binds to B7-H4-expressing tumor cells, triggers ADC internalization, and induces S-phase cell cycle arrest, cytotoxicity, and bystander killing effect. Mocertatug rezetecan (DAR4) exhibits dose-dependent tumor growth inhibition in breast cancer and endometrial cancer CDX models. It can be used in research related to platinum-resistant ovarian cancer, breast cancer, endometrial cancer, cholangiocarcinoma, and cervical cancer .
loading...
    loading...